NCT05848011 2026-04-17
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Completed
Clinical Trials
7 trialsNCT03431350 2026-04-13
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT04717154 2026-01-06
INSPIRE
Radboud University Medical Center
Phase 2 Completed
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated